vs
AAON, INC.（AAON）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AAON, INC.的1.8倍（$772.1M vs $424.2M），Revvity净利率更高（12.7% vs 7.6%，领先5.2%），AAON, INC.同比增速更快（42.5% vs 5.9%），过去两年AAON, INC.的营收复合增速更高（27.2% vs 9.0%）
AAON公司是商用及工业领域暖通空调设备专业生产商，总部位于美国俄克拉荷马州塔尔萨市，在得克萨斯州朗维尤、密苏里州帕克维尔、俄勒冈州雷德蒙德设有生产基地，全球员工约4000人，年销售额超8.8亿美元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AAON vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$424.2M
营收增速更快
AAON
高出36.6%
5.9%
净利率更高
RVTY
高出5.2%
7.6%
两年增速更快
AAON
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $424.2M | $772.1M |
| 净利润 | $32.0M | $98.4M |
| 毛利率 | 25.9% | — |
| 营业利润率 | 10.4% | 14.5% |
| 净利率 | 7.6% | 12.7% |
| 营收同比 | 42.5% | 5.9% |
| 净利润同比 | 29.7% | 3.9% |
| 每股收益（稀释后） | $0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAONRVTY
| Q4 25 | $424.2M | $772.1M | ||
| Q3 25 | $384.2M | $698.9M | ||
| Q2 25 | $311.6M | $720.3M | ||
| Q1 25 | $322.1M | $664.8M | ||
| Q4 24 | $297.7M | $729.4M | ||
| Q3 24 | $327.3M | $684.0M | ||
| Q2 24 | $313.6M | $691.7M | ||
| Q1 24 | $262.1M | $649.9M |
净利润AAONRVTY
| Q4 25 | $32.0M | $98.4M | ||
| Q3 25 | $30.8M | $46.7M | ||
| Q2 25 | $15.5M | $53.9M | ||
| Q1 25 | $29.3M | $42.2M | ||
| Q4 24 | $24.7M | $94.6M | ||
| Q3 24 | $52.6M | $94.4M | ||
| Q2 24 | $52.2M | $55.4M | ||
| Q1 24 | $39.0M | $26.0M |
毛利率AAONRVTY
| Q4 25 | 25.9% | — | ||
| Q3 25 | 27.8% | 53.6% | ||
| Q2 25 | 26.6% | 54.5% | ||
| Q1 25 | 26.8% | 56.5% | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 34.9% | 56.3% | ||
| Q2 24 | 36.1% | 55.7% | ||
| Q1 24 | 35.2% | 54.6% |
营业利润率AAONRVTY
| Q4 25 | 10.4% | 14.5% | ||
| Q3 25 | 11.3% | 11.7% | ||
| Q2 25 | 7.6% | 12.6% | ||
| Q1 25 | 10.9% | 10.9% | ||
| Q4 24 | 9.9% | 16.3% | ||
| Q3 24 | 20.0% | 14.3% | ||
| Q2 24 | 21.4% | 12.4% | ||
| Q1 24 | 17.9% | 6.8% |
净利率AAONRVTY
| Q4 25 | 7.6% | 12.7% | ||
| Q3 25 | 8.0% | 6.7% | ||
| Q2 25 | 5.0% | 7.5% | ||
| Q1 25 | 9.1% | 6.4% | ||
| Q4 24 | 8.3% | 13.0% | ||
| Q3 24 | 16.1% | 13.8% | ||
| Q2 24 | 16.7% | 8.0% | ||
| Q1 24 | 14.9% | 4.0% |
每股收益（稀释后）AAONRVTY
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $0.37 | $0.40 | ||
| Q2 25 | $0.19 | $0.46 | ||
| Q1 25 | $0.35 | $0.35 | ||
| Q4 24 | $0.31 | $0.77 | ||
| Q3 24 | $0.63 | $0.77 | ||
| Q2 24 | $0.62 | $0.45 | ||
| Q1 24 | $0.46 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.0K | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $895.0M | $7.3B |
| 总资产 | $1.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAONRVTY
| Q4 25 | $13.0K | $919.9M | ||
| Q3 25 | $1.0M | $931.4M | ||
| Q2 25 | $14.0K | $991.8M | ||
| Q1 25 | $994.0K | $1.1B | ||
| Q4 24 | $14.0K | $1.2B | ||
| Q3 24 | $15.0K | $1.2B | ||
| Q2 24 | $13.0K | $2.0B | ||
| Q1 24 | $8.4M | $1.7B |
股东权益AAONRVTY
| Q4 25 | $895.0M | $7.3B | ||
| Q3 25 | $863.1M | $7.4B | ||
| Q2 25 | $832.7M | $7.6B | ||
| Q1 25 | $815.9M | $7.6B | ||
| Q4 24 | $824.6M | $7.7B | ||
| Q3 24 | $796.9M | $7.9B | ||
| Q2 24 | $740.5M | $7.9B | ||
| Q1 24 | $784.8M | $7.8B |
总资产AAONRVTY
| Q4 25 | $1.7B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.4B | $12.4B | ||
| Q1 25 | $1.3B | $12.4B | ||
| Q4 24 | $1.2B | $12.4B | ||
| Q3 24 | $1.0B | $12.8B | ||
| Q2 24 | $1.0B | $13.4B | ||
| Q1 24 | $952.9M | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 0.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流AAONRVTY
| Q4 25 | $19.3M | $182.0M | ||
| Q3 25 | $12.3M | $138.5M | ||
| Q2 25 | $-21.8M | $134.3M | ||
| Q1 25 | $-9.2M | $128.2M | ||
| Q4 24 | $845.0K | $174.2M | ||
| Q3 24 | $63.8M | $147.9M | ||
| Q2 24 | $35.5M | $158.6M | ||
| Q1 24 | $92.4M | $147.6M |
自由现金流AAONRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率AAONRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度AAONRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率AAONRVTY
| Q4 25 | 0.60× | 1.85× | ||
| Q3 25 | 0.40× | 2.97× | ||
| Q2 25 | -1.41× | 2.49× | ||
| Q1 25 | -0.31× | 3.03× | ||
| Q4 24 | 0.03× | 1.84× | ||
| Q3 24 | 1.21× | 1.57× | ||
| Q2 24 | 0.68× | 2.87× | ||
| Q1 24 | 2.37× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAON
| AAON Oklahoma | $215.5M | 51% |
| Bas X | $106.1M | 25% |
| AAON Coil Products | $102.6M | 24% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
